ClinicalTrials.gg
Active, not recruitingNCT03987958REVIVEUpdated Jan 16, 2026

A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)

An observational study in Acute Myeloid Leukemia, sponsored by AbbVie. Active, not recruiting at 12 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by AbbVie · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Leukemia, Myeloid, Acute by AbbVie — 4 open to participants now, 9 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · AbbVie.

Planned enrollment
7th of 10
100 · median 113
Started
2019
with 4 others
Observational
10 of 43
1 open now
Registered
22nd of 43
by date

Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 5 that started in 2019, is one of 10 observational ones, and was the 22nd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 43 studies in Leukemia, Myeloid, Acute by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Leukemia, Myeloid, Acute by AbbVie, or all of them as a file.
02

Study summary

This study will describe the safety and effectiveness of venetoclax in AML patients in routine clinical practice in Israel. The decision to treat with venetoclax is made by the physician prior to any decision regarding participation in this study.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Acute Myeloid Leukemia, Venetoclax
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with AML treated with venetoclax in routine clinical practice

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant diagnosed with Acute Myeloid Leukemia (AML) and is eligible to receive venetoclax per Israel Ministry of Health.
  • Participant who will be treated with venetoclax and the decision to treat with venetoclax is made by the physician prior to any decision regarding participation in this study.

Exclusion criteria

Exclusion Criteria:

- Participant participating in an interventional trial within 30 days prior to starting venetoclax treatment.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)

Groups and cohorts

  • Venetoclax

    Participants in this observational study will receive treatment with venetoclax for AML. The decision to treat with venetoclax has been made independently from this observational study before participants are offered the opportunity to participate in this study.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival is defined as the time from the date of first treatment to the date of death from any cause.

    Time frame: Time from treatment to death from any cause, up to approximately 30 months

Secondary outcomes

  1. Percentage of participants achieving composite complete remission (CR or CRi)

    The percentage of participants achieving CR or CRi will be calculated based on the modified International Working Group (IWG) criteria for AML.

    Time frame: Approximately 30 months

  2. Time to transfusion independence

    Transfusion independence is defined as the time between date of first venetoclax treatment and absence of red blood cell (RBC) or platelet transfusion for any consecutive 8 and/or 16 week period.

    Time frame: Up to 30 months

  3. Percentage of participants achieving transfusion independence

    Transfusion independence is defined as the time between date of first venetoclax treatment and absence of red blood cell (RBC) or platelet transfusion for any consecutive 8 and/or 16 week period.

    Time frame: Up to 30 months

  4. Percentage of participants treated with venetoclax as compared to participants treated with other approved biologics

    The percentage of participants treated with venetoclax in combination with Hypomethylating Agents (HMAs) and Low Dose Cytarabine (LDAC) will demonstrate treatment patterns of prescribing physicians.

    Time frame: Up to approximately 30 months

  5. Change in patient reported outcomes for the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire CORE (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).

    Time frame: Week 0 to approximately 30 months

  6. Change in patient reported outcomes for the Euro Quality of Life 5 Dimensions 5 Levels Questionnaire (EQ-5D-5L)

    The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state.

    Time frame: Week 0 to approximately 30 months

07

Study locations

12 sites
08

References and documents

Publications

  • Wolach O, Levi I, Nachmias B, Tavor S, Amitai I, Ofran Y, Ganzel C, Zuckerman T, Okasha D, Hellmann I, Tadmor T, Dally N, Canaani J, Stemer G, Grunspan M, Berger AJ, Frankel N, Berelovich J, Bleterman A, Barak M, Cohen R, Moshe Y. Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study. Blood Adv. 2025 Apr 8;9(7):1544-1554. doi: 10.1182/bloodadvances.2024014014. PubMed 39637307 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2019 (actual). Primary completion is estimated for Jul 2027, 95 months after the start.

Of 160 observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 154. This study's planned 95 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2019
First posted
Jun 17, 2019
StartActual
Aug 8, 2019
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03987958
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 17, 2019
Start date
Aug 8, 2019
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jan 16, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion